<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Moscovitch-Lopatin M</submitter><funding>NHGRI NIH HHS</funding><funding>NINDS NIH HHS</funding><pagination>1134-40</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3795598</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>81(13)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>We measured the levels of mutant huntingtin (mtHtt) and total huntingtin (tHtt) in blood leukocytes from Prospective Huntington At-Risk Observational Study (PHAROS) subjects at 50% risk of carrying the Huntington disease mutation using a homogeneous time-resolved fluorescence (HTRF) assay to assess its potential as a biomarker.&lt;h4>Methods&lt;/h4>Peripheral blood mononuclear cells from consenting PHAROS subjects were analyzed by HTRF using antibodies that simultaneously measured mtHtt and tHtt. mtHtt levels were normalized to tHtt, double-stranded DNA, or protein and analyzed according to cytosine-adenine-guanine repeat length (CAGn), demographics, predicted time to clinical onset or known time since clinical onset, and available clinical measures.&lt;h4>Results&lt;/h4>From 363 ass</pubmed_abstract><journal>Neurology</journal><pubmed_title>HTRF analysis of soluble huntingtin in PHAROS PBMCs.</pubmed_title><pmcid>PMC3795598</pmcid><funding_grant_id>UO1NS071789</funding_grant_id><funding_grant_id>P01NS058793</funding_grant_id><funding_grant_id>HG02449-01</funding_grant_id><funding_grant_id>U01 NS071789</funding_grant_id><pubmed_authors>Goodman RE</pubmed_authors><pubmed_authors>Matson S</pubmed_authors><pubmed_authors>Moscovitch-Lopatin M</pubmed_authors><pubmed_authors>Shoulson I</pubmed_authors><pubmed_authors>Matson W</pubmed_authors><pubmed_authors>Rosas HD</pubmed_authors><pubmed_authors>Young AB</pubmed_authors><pubmed_authors>Hersch SM</pubmed_authors><pubmed_authors>Huntington Study Group PHAROS Investigators</pubmed_authors><pubmed_authors>Eberly S</pubmed_authors><pubmed_authors>Ritch JJ</pubmed_authors><pubmed_authors>Oakes D</pubmed_authors></additional><is_claimable>false</is_claimable><name>HTRF analysis of soluble huntingtin in PHAROS PBMCs.</name><description>&lt;h4>Objective&lt;/h4>We measured the levels of mutant huntingtin (mtHtt) and total huntingtin (tHtt) in blood leukocytes from Prospective Huntington At-Risk Observational Study (PHAROS) subjects at 50% risk of carrying the Huntington disease mutation using a homogeneous time-resolved fluorescence (HTRF) assay to assess its potential as a biomarker.&lt;h4>Methods&lt;/h4>Peripheral blood mononuclear cells from consenting PHAROS subjects were analyzed by HTRF using antibodies that simultaneously measured mtHtt and tHtt. mtHtt levels were normalized to tHtt, double-stranded DNA, or protein and analyzed according to cytosine-adenine-guanine repeat length (CAGn), demographics, predicted time to clinical onset or known time since clinical onset, and available clinical measures.&lt;h4>Results&lt;/h4>From 363 ass</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Sep</publication><modification>2026-05-02T09:38:30.503Z</modification><creation>2019-03-27T01:17:08Z</creation></dates><accession>S-EPMC3795598</accession><cross_references><pubmed>23966247</pubmed><doi>10.1212/WNL.0b013e3182a55ede</doi><doi>10.1212/wnl.0b013e3182a55ede</doi></cross_references></HashMap>